Le Lézard
Classified in: Health, Science and technology
Subject: SPECIAL NEWS EVENTS

Beleave Aims to Raise Awareness by Supporting Don't Drive High Campaign


TORONTO, ONTARIO--(Marketwired - Nov. 29, 2017) - Beleave Inc. ("Beleave" or the "Company") (CSE:BE)(CSE:BE.CN)(CSNX:BE)(OTCQX:BLEVF) is pleased to support initiatives like the "Don't Drive High" campaign that make the public aware of the potential repercussions to driving under the influence. As we get closer to the legalization of recreational cannabis in Canada in July 2018, Ontario is planning on introducing tougher penalties for drivers caught under the influence.

"It is important to us that the implementation of recreational cannabis in Canada occurs as smoothly as possible. With all eyes on the industry we want to put our best foot forward," stated Beleave Chief Science Officer Roger Ferreira, "Our message is simply that cannabis should be used responsibly. Impaired driving, which includes driving under the influence of cannabis, is illegal. However, there is a segment of the population that may be unaware of this or feel they are more attentive drivers after consuming cannabis. Our intention is to inform all drivers of the facts in an effective and memorable way."

The Company's goal in supporting the campaign is not to sell the advertised "Consequence Strains", rather the goal, in partnership with R.I.D.E. CHECKS, is to start an important conversation, raise awareness and protect cannabis users from the dangers associated with driving impaired.

About Beleave

Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.


These press releases may also interest you

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....

at 17:00
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors. On October 5, 2023, NOVA OMS became aware of unusual activity on...

at 17:00
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...



News published on and distributed by: